Dishman Carbogen Amcis Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "PRESS RELEASE ON UN-AUDITED FINANCIAL RESULT FOR THE SECOND QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025 ".
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dishman Carbogen Amcis has filed a press release dated November 5, 2025 with the stock exchange, covering its un-audited financial results for the second quarter and the half-year ended September 30, 2025. This is a standard quarterly earnings disclosure for a listed company. The filing itself does not contain the detailed numbers — those would be in the accompanying press release. The company operates in the pharmaceutical contract development and manufacturing (CDMO) space. Investors will need to refer to the full results document for revenue, EBITDA, profit after tax, and segment-wise performance.
No immediate price impact can be judged from this notice alone, as it only confirms that results have been filed. Actual market reaction will depend on the numbers in the press release — whether revenue and profit beat or miss street expectations.